incobotulinumtoxinA

08/01/2001 - "In both disease types, BoNT/A treatment led to a significant improvement in several HRQL dimensions, in particular providing moderate to marked effect sizes in the fields of mental health and pain. "
12/01/2021 - "BoNT-A induced a significant improvement in dystonic symptoms, as well as in psychiatric disturbances, pain, and disability. "
01/01/2021 - "Treatment with BoNT/A clinically and significantly improved the frequency and pain severity of PTH compared to placebo in military veterans. "
02/01/2019 - "Treatment with IA BoNT/A decreased pain behaviors but only forelimb weight bearing showed a significant improvement. "
01/01/2019 - "BoNT-A proved to be a good therapeutic option in relieving pain with improved quality of life for these patients."

08/01/2016 - "High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective?"
04/01/2010 - "Following treatment with BoNT-A, there was a significant improvement in kinematics in patients with stroke, while in the control group, performance remained unchanged. "
11/01/2018 - "Current evidence from the literature suggests that higher doses of BoNT-A are effective in reducing spasticity of upper and lower limbs after stroke, with rare occurrence of mild adverse effects. "
07/01/2018 - "BoNT-A treatment for lower-limb spasticity, combined with intensive rehabilitation, was effective in improving spasticity and the 6MD compared with intensive rehabilitation alone in patients with chronic stroke."
02/01/2019 - "However, controversy remains about improvement in motor function relative to post-stroke spasticity reduction after BoNT-A treatment."

01/01/2009 - "Our study showed a trend towards a reduced attack rate with verum but did not show any statistically significant efficacy of BoNT-A in the prophylactic treatment of migraine."
04/30/2020 - "BoNT-A has proved effective in several neurological conditions and, more recently, also in chronic migraine. "
01/01/2007 - "BoNT-A injection was an effective and safe treatment for migraine prophylaxis among the Japanese population. "
05/01/2013 - "In this study, two groups of patients were treated with different dosages of BoNT A to verify the efficacy for chronic migraine. "
12/01/2007 - "Our study was designed to evaluate the efficacy of BoNT-A in the treatment of transformed migraine (TM) in a population of Taiwanese patients. "

07/01/2002 - "Sixteen patients suffering from spasmodic torticollis were selected: in 2 patients, BoNT/A treatment continued to be effective, in 9 patients, the treatment effect was impaired, and in 5 patients, secondary treatment failure developed. "
09/15/2011 - "The objective of this study was to compare the safety and efficacy of incobotulinumtoxinA (120 U, 240 U; Merz Pharmaceuticals) to placebo in subjects with cervical dystonia (CD). "
01/01/2023 - "This study was conducted to better understand BoNT-A injection patterns, use of healthcare services, and the resulting costs in patients with spasticity or cervical dystonia."
01/01/2017 - "However, by combining results with other studies on BoNT/A-treated Caucasian patients with cervical dystonia (CD), we found that, among Caucasian patients treated with BoNT/A, DQA1*01:02 and DQB1*06:04 were higher in Ab-positive than in Ab-negative patients. "
12/01/2015 - "In cervical dystonia, when comparing the effects of BoNT/A and BoNT/B, results are more variable, some studies reporting roughly similar peak effect and overall duration (at a ratio of 1:66, others reporting substantially shorter duration of BoNT/B than BoNT/A (at a ratio 1/24). "

01/01/2022 - "The open-label phase 3 "Treatment with IncobotulinumtoxinA in Movement Open-Label" (TIMO) study investigated longer-term safety and efficacy of incobotulinumtoxin A in children/adolescents with cerebral palsy (CP). "
01/01/2022 - "Safety and efficacy of repeat long-term incobotulinumtoxinA treatment for lower limb or combined upper/lower limb spasticity in children with cerebral palsy."
04/08/2020 - "Our clinical experience indicates that incobotulinumtoxinA is a well-tolerated treatment option for focal spasticity in children with cerebral palsy. "
01/01/2017 - "The results have shown the safety and efficacy of xeomin in the treatment of gastrocnemius spasticity in pediatric patients with cerebral palsy. "
01/01/2022 - "This analysis provides pooled safety data from phase 3 trials of children/adolescents (2-17 years), investigating incobotulinumtoxinA for the treatment of spasticity associated with cerebral palsy (at doses ≤20 U/kg (max. "